Free Trial

Medicis Pharmaceutical Q3 2024 Earnings Report

Medicis Pharmaceutical EPS Results

Actual EPS
$0.76
Consensus EPS
$0.68
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Medicis Pharmaceutical Revenue Results

Actual Revenue
$391.20 million
Expected Revenue
$378.62 million
Beat/Miss
Beat by +$12.58 million
YoY Revenue Growth
+31.90%

Medicis Pharmaceutical Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Remove Ads

Medicis Pharmaceutical Earnings Headlines

DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
See More Medicis Pharmaceutical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicis Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicis Pharmaceutical and other key companies, straight to your email.

About Medicis Pharmaceutical

Medicis Pharmaceutical (NYSE:MRX)oration (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).

View Medicis Pharmaceutical Profile

More Earnings Resources from MarketBeat